Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadjuvant chemoradiotherapy
Intratumoral Adjuvant Chemotherapy With Doxorubicine In ...
Transcript of Intratumoral Adjuvant Chemotherapy With Doxorubicine In ...
Turkish Neurosurgery 4: 145 - 149, 1993 Oktar: Intratumaral Adjuvant ADM Chematherapy
Intratumoral Adjuvant Chemotherapy With DoxorubicineIn Glioblastoma Multiforme and Anaplastic Astrocytoma
NEZIH OKTAR. ISMAIL TANER. IZZET ÖVÜL. EREN DEMIRTAS
Ege University, Medical School. Departments of Neurosurgery (NO, IT, IÖ), and Pathology (ED), Bornova, Izmir, Türkiye
Abstract : Intratumoralloeal chemotherapy was applied as adjuva nt treatment to 20 patient with reeurrent types of anaplasticastroeytoma (AG3-4) and glioblastoma multiforme (GBM). Amultiport catheter was implanted into the tumour and a portableAmmaya reservoir was plaeed under the sealp over the ap eneraniotomy bone flap. Doxorubidne (Adriamydne) was given0.5mg per day for ten day s ,and a total of ten treatments wereprogrammed monthly for each ease. Pre-operative Karnofsky performanee score was between 60 and 70%.Control CT seans of the
patients showed the tumour to be progressive in 40 %. regressive
INTRODUCTION
Several chemotherapeutic drugs have been usedeither as single agents or as combinationchemotherapy in the treatment of malignant gliomas.The antineoplastic activity of doxorubicine(Adriamycine=ADM) (an antiturnoral agent of antibiotic origin isolated from streptomyces peucetiusvar. caesius) has been clearly demonstrated (1).it hasthe ability to show specific immunosuppressive activity as an inhibitor of reverse transaiptase enzyme.ADM is not a phase-specific agent. Besides bonemarrow depression, stomatitis and hyperurichaemiahave been reported as known side effects. Becauseof its poor penetration into blood-brain barrier andsevere neurotoxicity. ADM is not considered suitablefor systemic brain tumour chemotherapy (18).On theother hand. its effectiveness in the prevention ofsystemic metastases and in combination therapy asadjuvant chemotherapy has been reported (23.24).
Instilling drugs directly into the CSF or gliomatissue has been repeatedly shown to inaease survival
in 30%, and stable in 30%. In two patients alacal sealp infectionand a eerebellar abseess due to Noeardia asteroides developed ascomplieations of the treatment, but no other sistemie or loeal sideeffeets were deteeted. Mean survival in the anaplastic astroeytomaand GBMgroups was 98.9 and 46.1 weeks respeetively. In conclusion, intratumoral doxorubidne treatment was found to be effee
tive against systemie Lv. administratian in the anaplasticastroeytoma group rather than the GBM group.Key words: Chemotherapy, intratumoral, Doxorubidne, Cerebellarabseess
and improve quality of life by diminishing the disadvantages due to the blood-brain barrier (4.7,9).Previous attempes at intratumoral chemotherapy forbrain tumours have been reported for a variety ofdrugs. including bleomycin (2),methotrexate (MTX)(7,10,24.28,29). cisplatin (3), interferon andnitrosoureas (17.32).
In this study. the antiturnoral effect of doxorubicine (Adriamycine=ADM) as intratumorallocalchemotherapy was investigated in twenty anaplasticastrocytoma and glioblastoma multiforme (GBM)patients.
MATERIALS AND METHODS
Twelve anaplastic astrocytoma and eightglioblastoma patients were included in the programme. Theyall had been irradiated and receivedCCNU chemotherapy with 1iomglm2 doses beforerecurrent tumour was diagnosed in control CT-scans.There were II women and 9 men with a mean ageof 48 years and mean performance status of 64.4%
145
Turkish Neurosurgery 4: 145 - 149, 1993
on the Karnofsky scale. Histopathological diagnosiswas based on the WHO classification of 1990 with
an malignant astrocytoma i GBM rate of 60%. Twopatients had been operated four times, six threetimes. and ten patients twice.
Intratumoral chemotherapy was started on the second post-operative day after a control of CT-sean forthe prompt site of the catheter. Microinjections ofdoxorubicine were administered per-operatively toeach recurrent glioma case. Doxorubicine(Adriamydne. Farmitalia), was given post-operativelythrough the Ommaya reservoir (20)in doses of 0.5mgdaily for LO days and repeated monthly ten times.ECG.blood uric acid. creatinin. white blood cells and
platelets were monitored routinely throughout thedrug administration.
In addition, ADM 60-75mglm was administeredintravenously in ten recurrent anaplastic astrocytomaand ten GBM as a consequent comparison group. Inthese systemic ADM treated groups , Karnofsky performance scale mean score were 68,3% and 60%.
respectively.
CT-scanning was performed bimonthlypostoperatively with and without cantrast enhancement to measure the size of the the tumour. Median
survivals were ca1culated using the Kaplan-Meiermethod (12).For statistical analysis , student t , F ande tests were used for the significant differences.
RESULTS
CT-seans of a right-sided occipital anaplasticastrocytoma case before and after the intratumorallocal chemotherapy treatment was shown in Figure1 a. b. The maximal total dose of 50mg ADM was
Oktar: 1ntratumoral Adjuvant ADM Chemotherapy
reached only twice in two anaplastic astrocytoma patients. The mean total dose was 22.5mg.
Mild side effects were headache in three patients.and slight hyperurichaemia in one. In one patient.local irritative infection due to leakage of ADM to thescalp was observed. In another patient. an asepticmeningitis occurred and was treated with corticasteroids. One patient developed a left sidedcerebellar abscess which was removed by subocdpital aaniectomy (Figure 2).Culture of the spedmenrevealed Nocardia astroides as a severe complicationof the treatment. This camplication developed otherthan the local site of the administered drug may beexplained in terms of its immunosuppressive effect.All other side effects disappeared in the first 72hours.Mean survival was 98.9 weeks in the anaplastic astrocytoma (AG3-4)group and 46.1 weeks in the theGBM group, Comparison of the survival rates of thepatients receiving systemic (i.v.) and intratumoralADM chemotherapy revealed a signincant effectiveness of local as opposed to the systemic chemotherapy in the anaplastic astrocytoma group (p<0.5). Nosignincant statistical difference was found in the GBMpatient group (p > 0,5) (student t test) (Table I).
Median survivals were ca1culated as 67.5 weeks
in locally treated and 60 weeks in intravenouslytreated malignant astrocytoma groups, and 44.5 and45 weeks in the GBMgroups. respectively (Figure 3).CT seans of the patients showed: tumours to be progressive 40%, regressive 30% and stable 30% .
Histopathological investigation ofbiopsy materialafter intratumoral ADM administration revealed
some tissue necrosis and hyalinisation processes inthe vessels. as shown in Figures 4a. b.
Fig. la, b: CT-sean showing decrease in the size of an anaplastic astrocytoma before (a)and six montbs alter (b)mtraturn oral ADM treatment.
146
Turkish Neurosurgery 4: 145 - 149, 1993 Oktar: Intratumoral Adjuvant ADB Chemothetrapy
Fig. 3 : Kaplan-Meler survival curves for Anaplastic astrocytoma(AA) and GBMpatients treated with intratumoral or syste
mic ADM chemotherapy
(62.0)
Groups & Median Survlval <in w··"i·
~ iniralumoral AA (67,5)
-+-Inlratumoral GBM (44,5)
Weeks
15 30 45 60 75 QO 105120135150165180195
10
TumoaB NofofIdean ageIdeanIdeanIdedianp
paoents
KmiofslySamia!Samia!iINdemi
(n)
Perioiiiwiceiinweeks'inweeks'resi'
SeoreIntratumoral ADM Chemotherapy Anaplastic
1246.166%93,9'675 weeksp<O.5
astrocyioma
weeks
'(Wopaoen~are stillhl'IOgGSM
8SU633%46,1 weeks44, weeksp>0,5
Systemic (Lv,) ADM Chemotherapy Anaplastic
10474683%62,0 weeks60,0 weeksp<0,5
astrixytoma GBM
10,2)60%42,9 weeks450 weeksp>0,5
Fig.2: Ct sean of a patient showing a left sided cerebellar abscess
during intratumoral ADM chemotherapy as a complicationof the procedure,
Table i: Comparison of Mean and MedianSurvivals of Cases Treated With Adjuvant
Intratumoral and Systemic ADM Chemotherapy
Fig. 4 a, b: Tissue necrosis (A) and hyalinisation processes in the vessels (B)after intratumoral ADM chemotherapy in biopsy materiaL.
147
Turkish Neurosurgery 4: 145 - 149, 1993
DlSCUSSION
During the pa st decade there has been great interest in identifying the best drug for thechemotherapy ofbrain tumours, The basic prindpleof chemotherapy is that the drug mu st reach all partsof the tumour. and the side effects must be minimaL.
The blood-brain barrier prevents the delivery ofchemotherapeutic agents into the brain tissue andCSF is not an adequate pathway to reach solidtumours within the brain (29), In 1968, Ommayadescribed his initial experience with the insertion ofa CSF reservoir and a manual pump, In that earlyreview, there was a complication rate of 28% in 60patients. consisting largely of seizures and infection;in addition. pump failure occurred in 23% (23). Thesurgical technique was altered in subsequent years.showing more favourable complication rates inrecently published articles (8.16). Direct delivery ofdrugs into a brain tumour through multiple implanted catheters by a stereotactic procedure hasbeen tried (9).but a few biopsi es have be en performed after intratumoral chemotherapy (19). MTX.Bleomydn. Cisplatin. BCNUand other water-solublenitrosoureas and ADM were the antineoplastic drugsused for this purpose (5,8.13.20.26.27.28.32.33),
We believe that 0.5mg ADM was not adequateas a single dose. In same studies,mainly carried outby the Japanese researchers (11.25.30.31). the totaldose of ADM in intratumoral administration was
reported as 5-lOmg. Our total dose was much higher.ranging from 30 to 50mg (mean 22,5 mg), Throughoutthe study the postulated total dos e of 50mg was notachieved and no seizures.cardiotoxidty or nephrotoxidty occurred in any of the cases, Yoshida reportedalocal chemotherapy study in 79 patients; 63 withADM. 5 with a combination of ADM and bleomydn,7 with bleomydn and 4 with MTX and reported 8local infections and 4 meningitis cases as complication s of this procedure (33).Mean survival was 806days in the AG3 and 757 days in the AG4 groupwhich was close to our findings (692 days in theanaplastic astrocytoma group).
Surgical implantation of biodegradable polymercontaining chemotherapeutic drugs into the tumourmay be considered as a therapeutic option (8 ). Withthis technique Kuba reported 91%of 18 months' survival in 91% of 20 anaplastic astrocytoma cases and12 months in 47% of 23 GBM patients with intratumaral ADM treatment (14).Median survival of
148
Oktar: Intratumaral Adjuvant ADM Chematherapy
patients treated with surgery alone is approximately 20 weeks in GBMpatients. and surgery plus radiation therapy. 45-50 weeks (6).With our method themedian survival was 44.5 weeks in the GBMand 67.5
weeks in the anaplastic astrocytoma group.
Apart from unexpected complications. our studyshowed that the dose and side effects of the drugwere minimal in intratumoral chemotherapy. Serialstereotactic biopsies may help to determine the doseof the drug in the tumour and pathological foilow-up.
In conclusian. evaIuatian of the mean survival
rate of the patients, though the sizes of the groupswere smail. showed that intratumoral ADM treat
ment was significantly more effective in the recurrent anaplastic astrocytoma group than the GBMgroup.
Correspondence, Dr. Nezih OktarEge University Medical schoolDept. of NeurosurgeryBornova· 35100. Izmir. Türkiye
REFERENCES
1. Benjamin RS. Wiernik PH. Bachar NR; Adriamycinchemotherapy ; effieacy. safety. and pharmacologic basis ofintermittent single high dosage schedule. Cancer 33:19-27.1974
2. Bosch DA. Hindmarsch TH. Larsson ST. Backlund EO; lntra
neoplastic administration of bleomydn in intracerebralglioma:A pilot study. Neurochirurgica (Suppl 30):441-444.1980
3. Beuvier G.Penn R.KroinJS.BeiqueR.Guerard MJ;Direct delivery, of medication into a brain tumor through multiple chronical·ly implanted catheters. Neurosurgery 20:286·291,1987
4. Dakhil S..Ensminger W. Kindt G. Niedorhuber J; Implantedsystem for intraventricular drug infusion in CNS tumours.Cancer Treat Rep 65:401-411,1981
5. Diemath HE; Lokale Anwendung von Zytostatika nach Extirpation von Glioblastomen. Wiener Klinische Wochenschrift:99:674-676.1987
6. Fountailer G. Karavaiis A. Makrantonakis P; Postoperative intracarotid chemotherapy followed by radiation therapy in patients with malignant gliomas. Res Cancer Treat 3:332-337.1991
7. Garfield J.Dayan AD; Postoperative intraeavitary chemotherapyof malignant gliomas. A preliminary study using methotrexate. J Neurosurg 39:315-322. 1973
8. Grossman SA,Reinhard C.Calvin M; The intracerebral distribu
tion ofBCNU delivered by surgieally implanted biodegradablepolymers. J Neurosurg 76:640-647. 1992
9. Hagen NA; Computer assisted stereotaetic placement of ommaya reservoirs for delivery of chemotherapeutic agents ineancer patients. J Neuro-oncol 5:273-276. 1987
10. Heppner F.Diemath HE; Lokale Chemotherapie der Him·tumoren. Acta Neurochir (Wien) 11:287-293. 1963
lL. !toh Y; Treatment of malignant brain tumor by loeal injeetionof adriamydn. Nippon Ika Daigaku Zasshi 47:527-537. 1980
Turkish Neurosurgery 4: 145 - 149, 1993
12. Kaplan EL, Meier P; Non-parametric astimation from incomplete observations. J Am Statist Assoc 53:457-481. 1958
13. Kroin JS,Penn RD; Intracerebral chemotherapy; chronicmiaoinfusion of dsplatin. Neurosurgery 10:349-354, 1982
14. Kubo O; Treatment of malignant brain tumors with slowlyrelasing anticancer drug-polymer composites, No Shinkei Geka14;1189-1195, 1986
15. Lazorthes Y, Sallerin-Caute J,Verdie JC..Bastide R; Advancesin drug delivery systems and applieations in neurosurgery.Symon L (Ed), in ,Advances and technical standards inneurosurgery.Vol:18, Springer-Verlag 1991. 180-182
16, Machado M. Saleman M, Kaplan RS;Expanded role of the CSFreservoir in neuro-oncology; indieations,eauses of revision andcomplications. Neurosurgery 17:600-603, 1985
17. Naganuma H.Kimurat R, Sasaki A,Fukamachi A.NukuiRTasaka K; Complete remission of recurrent glioblastomamultiforrne following loeal infusions of lymphokine activatedkiller cells. Aeta Neurochir (Wien) 99:157-160, 1989
18. Neuwelt EA. Pagel M,Barnett P; Pharrnacology and toxidty ofintraearotid adriamydn administration following osmoticblood-brain barrier modifieation. Cancer Research 41:4466-70,1981
19. Nierenberg D. HarbaughR, Maurer H, ReederT, Scott G. FratkinJ. Newman E; Continuous intratumoral infusion of MTX forrecurrent glioblastoma;A pilot study. Neurosurgery28:752-761.1991
20. Ommaya AK; Implantation devices for chronic access and drugdelivery to the central nervous system. Cancer Drug Delivery1;169-179.1979
21. Petrovid JN, Ilsen HW; Chemotherapy of brain tumors. Frowein RA (Ed), in Advances in Neurosurgery. 5 Ed.. SpringerVerlag, 1978. 292
Oktar: Intratumoral Adjuvant ADM Chemotherapy
22. Poullart P. Mathe G, Poisson M, Buge A.; Essai de traitmentdes glioblastomes de l'aduIte et des metastases cerebrales parI'assodation d'adriamydne, de VM 26 et de CCNU.Presse Med5;1571-6. 1976
23. Ratcheson RA, Ommaya AK; Experience with subcutaneouscerebrospinal reservoir. N Eng J Med 279:1025-1031.1968
24. Ringkjob R; Treatment of intraaanial gliomas and metastaticcardnomas by loeal applieation of eytostatic agents. Aeta NeurolScand 44:318-322, 1968
25. Shimura T,Nakazawa S; Intraneoplastic local injection ofadriamydn for malignant brain turnor chemotherapy. A clinicopathological study. Neurol Surg 8:35-42, 1980
26. Steward DJ,Maroun JA.Peterson E; Adriamydn in the treatment of malignant meningiomas. J Neuro-oncol 2;289, 1984
27. Steward DJ; Combined intraommaya MTX,cytosinearabinoside,hidrocortisone and thio-TEPA for meningeal involvement by malignandes, J Neuro-oncol 5;315-322.1987
28. Tator CH; Therapy of an experimental glioma with systemicor intraneoplastic MTX of radiation. J Neurosurg 46;175-184.1977
29. Weiss SR, Raskind R; Treatment of malignant brain turnors
by loeal MTX.A preliminary report. Int Surg 51:149-155.196930. Werner P.Peiffer J; Intratumoral histologic heterogeneity of
gliomas. Cancer 64:442-447. 198931. Wilkinson HA; Foeal chemotherapy of brain tumours using
serniperrneable membranes J Neur Neurosurg Psychiatry40:389-394,1977
32. Yamashima T.Yamashita J,Shoin K;Neurotoxidty ofIoeal adrninistration of two nitrosoureas in malignant gliomas.Neurosurgery 26:794-800. 1990
33. Yoshida D; clinieal research of the treatment of malignantgliomas by local administration of adriamydn.A statistiealstudy of 118eases. Nippon ika Daigaku Zasshi 55:544-554.1988
149